Stay updated on SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial

Sign up to get notified when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The study details page shows no significant updates; core information including eligibility criteria and primary outcomes appears unchanged.
    Difference
    0.4%
    Check dated 2025-10-27T21:02:43.000Z thumbnail image
  4. Check
    36 days ago
    Change Detected
    Summary
    Version bump to v3.2.0 accompanied by a government-operating-status notice; replaces the earlier v3.1.0 tag.
    Difference
    3%
    Check dated 2025-10-06T08:58:05.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    - Updated version from v3.0.2 to v3.1.0. - No other content changes detected.
    Difference
    0.2%
    Check dated 2025-09-29T07:29:17.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Revision: v3.0.2 is now displayed, replacing v3.0.1, and the Back to Top element was removed; this is a minor update with no changes to core content, pricing, stock availability, or time slot information.
    Difference
    0.2%
    Check dated 2025-09-14T23:11:02.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.
    Difference
    0.2%
    Check dated 2025-09-07T19:46:30.000Z thumbnail image
  8. Check
    72 days ago
    Change Detected
    Summary
    The web page has been updated to include new drug information for Rituximab and spartalizumab, as well as additional resources related to Follicular lymphoma and various biological factors. However, it has removed previous references to Pembrolizumab and certain genetic disease resources.
    Difference
    4%
    Check dated 2025-08-31T12:32:30.000Z thumbnail image

Stay in the know with updates to SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.